Cited by 878Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

Seeman, P., Lee, T.·1975·Science

DOI 10.1126/science.1145194

Open this paper in CoChat — free account

Abstract

Neuroleptic (antipsychotic) drugs inhibited the electrically stimulated release of [3 H]dopamine from rat striatal slices. The concentrations for 50 percent inhibition (ranging from 11.5 nanomolar for spiroperidol to 800 nanomolar for thioridazine) correlated closely with the average daily dosages of 25 neuroleptic drugs used clinically for schizophrenia. The correlation includes butyrophenones, phenothiazines, reserpine, pimozide, clozapine, and (+)-butaclamol. Clinically inactive isomers [trans-thiothixene,trans-flupenthixol, and (-)-butaclamol] required 20 to 1000 times higher concentrations than the active isomers to inhibit release. Compared to the inhibition of [3 H]dopamine release, much higher neuroleptic concentrations were needed to inhibit the electrically stimulated release of other neurotransmitters—[3 H]acetylcholine, [3 H]GABA (γ-aminobutyric acid). The neuroleptic drugs may block the presynaptic coupling between impulse and neurosecretion.

Integrity signals

Registry

Crossref · 10.1126/science.1145194

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Membrane Actions of Anesthetics and Tranquilizers
Seeman, P. M. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06931-5 · Cited by 2,241
Self-citation
Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse Brain
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,156
DOPAMINERGIC NEURONS: EFFECT OF ANTIPSYCHOTIC DRUGS AND AMPHETAMINE ON SINGLE CELL ACTIVITY
Bunney, B. S., Walters, J. R., Roth, R. H., & Aghajanian, G. K. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29539-8 · Cited by 1,283
Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
Andén, N., Butcher, S. G., CORRODI, H., Fuxé, K., & Ungerstedt, U. (1970) · European Journal of Pharmacology · doi:10.1016/0014-2999(70)90006-3 · Cited by 1,026
Drugs, Neurotransmitters, and Schizophrenia
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. A. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.
Jm, V. R. (1966) · PubMed · Cited by 508
Dopamine-Sensitive Adenylate Cyclase in Mammalian Brain: A Possible Site of Action of Antipsychotic Drugs
Clement‐Cormier, Y. C., Kebabian, J. W., Petzold, G. L., & Greengard, P. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1113 · Cited by 452
Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity
Kehr, W., Carlsson, A., Lindqvist, M., Magnusson, T., & Atack, C. (1972) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1972.tb09104.x · Cited by 417
IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS.
Janssen, P. A., Cj, N., & Schellekens, K. H. L. (1965) · PubMed · Cited by 348
Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
Matthysse, S. (1973) · PubMed · Cited by 338

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 9

Aghajanian, G. K., Frontiers in Neurology and Neuroscience Research: 4 (1974).
FARNEBO, L. O., ACTA PHYSIOLOGICA SCANDINAVICA 371: 19 (1971).
FARNEBO, L. O., ACTA PHYSIOLOGICA SCANDINAVICA 371: 35 (1971).
Munkvad, I., The Neuroleptics. Modern Problems in Pharmacopsychiatrv 5: 44 (1970).
RITCHIE, J.M., ON ACTIVE STRUCTURE OF LOCAL ANESTHETICS, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 133: 241 (1961).
SEEMAN, P, FEDERATION PROCEEDINGS 33: 246 (1974).
SOTELO, C, ULTRASTRUCTURAL IDENTIFICATION OF NIGRAL DOPAMINERGIC CELLS IN RAT, JOURNAL DE PHARMACOLOGIE 5: 55 (1974).
STAWARZ, R.J., SIGNIFICANCE OF INCREASE OF HOMOVANILLIC-ACID (HVA) CAUSED BY ANTIPSYCHOTICS IN CORPUS STRIATUM AND LIMBIC FOREBRAIN, FEDERATION PROCEEDINGS 33: 246 (1974).
ZIVKOVIC, B, SPECIFIC ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE (TH) BY NEUROLEPTICS, FEDERATION PROCEEDINGS 33: 536 (1974).

Sorted by citations

Items 101–200 of 878

Classics in Chemical Neuroscience: Clozapine
Wenthur, C. J., & Lindsley, C. W. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400121z · Cited by 147
Glutamate-mediated excitotoxicity in schizophrenia: A review
Plitman, E., Nakajima, S., de la Fuente‐Sandoval, C., Gerretsen, P., Chakravarty, M. M., Kobylianskii, J., Chung, J. K., Caravaggio, F., Iwata, Y., Remington, G. J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.015 · Cited by 150
“The clinical effects of dopamine receptor antagonists have provided the basis for the dopamine hypothesis of schizophrenia (Creese et al., 1976; Seeman and Lee, 1975), which posits that patients with the illness have aberrant functioning of the dopaminergic system (Abi-Dargham et al.”
Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT
Laruelle, M. A., Abi‐Dargham, A., van Dyck, C. H., Gil, R. B., D’Souza, D. C., Krystal, J. H., Seibyl, J. P., Baldwin, R. M., & Innis, R. B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00257-7 · Cited by 147
“For decades, the main support for this hypothesis was the correlation between clinical doses of antipsychotic drugs and their potency to block dopamine D2 receptors (Creese et al 1976; Seeman and Lee 1975), and the psychotogenic effects of dopamine-enhancing drugs, such as amphetamine (for review see Angrist and van K…”
Background
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis
Howes, O. D., Montgomery, A. J., Asselin, M., Murray, R. M., Grasby, P. M., & McGuire, P. K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.191.51.s13 · Cited by 144
Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features
Forsyth, J. K., & Lewis, D. A. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.06.006 · Cited by 145
Is GABA release modulated by presynaptic receptors?
Mitchell, P. R., & Martin, I. L. (1978) · Nature · doi:10.1038/274904a0 · Cited by 143
Role of Dopamine D2 Receptors for Antipsychotic Activity
Ginovart, N., & Kapur, S. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_2 · Cited by 141
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
Paz, R. D., Tardito, S., Atzori, M., & Tseng, K. Y. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.005 · Cited by 145
“…that first and second generation antipsychotic drugs exert anti-DA effects, mainly by targeting D2 over D1 receptors (Creese et al., 1976, Seeman and Lee, 1975), prolonged blockade of D2 receptors can also lead to decreased expression of PFC D1 receptors (Castner et al., 2000, Lidow et…”
Background
Neurochemical brain imaging investigations of schizophrenia
Soares, J. C., & Innis, R. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00015-3 · Cited by 142
Brain mechanisms of amphetamine-induced anorexia, locomotion, and stereotypy: A review
Cole, S. O. (1978) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(78)90050-7 · Cited by 140
Role of dysbindin in dopamine receptor trafficking and cortical GABA function
Ji, Y., Yang, F., Papaleo, F., Wang, H.-X., Gao, W., Weinberger, D. R., & Lu, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904289106 · Cited by 141
“The D2 family of dopamine receptors has long been considered as a key therapeutic target for schizophrenia (39).”
Background
Inverse Agonist Actions of Typical and Atypical Antipsychotic Drugs at the Human 5-Hydroxytryptamine2C Receptor
Rauser, L., Savage, J. E., Meltzer, H. Y., & Roth, B. L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29304-6 · Cited by 140
Effect of Risperidone on Hostility in Schizophrenia
Czobor, P., Volavka, J., & Meibach, R. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199508000-00002 · Cited by 139
Parkinsonism in neuroleptic-naive schizophrenic patients
Caligiuri, M. P., Lohr, J. B., & Jeste, D. V. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1343 · Cited by 137
Prefrontal Cortical Projections to the Midbrain in Primates: Evidence for a Sparse Connection
Frankle, W., Laruelle, M., & Haber, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300990 · Cited by 141
“The ‘classical’ DA hypothesis proposed that there is a hyperactivity of DA transmission, which is responsible for the positive symptoms (Carlsson and Lindqvist, 1963; Seeman and Lee, 1975; Creese et al, 1976).”
Background
Drug models of schizophrenia
Steeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 143
“With chronic dosing, the PPI and stereotyped behaviours occur at increasing frequency and duration over time [Segal and Mandell, 1974].”
Background
Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain
Kaalund, S. S., Newburn, E. N., Ye, T., Tao, R., Li, C., Deep-Soboslay, A., Herman, M. M., Hyde, T. M., Weinberger, D. R., Lipska, B. K., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.165 · Cited by 132
Finding schizophrenia genes
Kirov, G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24759 · Cited by 129
The Dopamine Hypothesis: An Overview of Studies With Schizophrenic Patients
Haracz, J. L. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.3.438 · Cited by 128
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide
Abi-Dargham, A., Kegeles, L. S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, V., O'Flynn, K., Koenigsberg, H. W., Van Heertum, R., Cooper, T., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.018 · Cited by 128
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders
Nikolaus, S., Antke, C., & Müller, H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.009 · Cited by 128
Striatal Presynaptic Dopamine in Schizophrenia, Part I: Meta-Analysis of Dopamine Active Transporter (DAT) Density
Fusar‐Poli, P., & Meyer‐Lindenberg, A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr111 · Cited by 125
Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia.
Huttunen, J., Heinimaa, M., Svirskis, T., Nyman, M., Kajander, J., Forsback, S., Solin, O., Ilonen, T., Korkeila, J., Ristkari, T., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.017 · Cited by 128
Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency
Enna, S. J., Bennett, J. P., Burt, D. R., Creese, I., & Snyder, S. H. (1976) · Nature · doi:10.1038/263338a0 · Cited by 122
Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study
Iwata, Y., Nakajima, S., Plitman, E., Caravaggio, F., Kim, J., Shah, P., Mar, W., Chavez, S., Luca, V. D., Mimura, M., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.009 · Cited by 121
D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry
Kisilevsky, A. E., Mulligan, S. J., Altier, C., Iftinca, M., Varela, D., Tai, C., Chen, L., Hameed, S., Hamid, J., MacVicar, B. A., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.03.002 · Cited by 127
“Disturbances in dopaminergic signaling are implicated in neuropathological disorders, including schizophrenia, Parkinson’s disease, and addiction (Bernheimer et al., 1973; Birkmayer and Hornykiewicz, 1961; Carlezon et al., 1995; Creese et al., 1976; Hoebel et al., 1983; Phillips et al., 1994; Seeman and Lee, 1975).”
Background
The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders
Jones, D. N., & Raghanti, M. A. (2021) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2021.101957 · Cited by 122
Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models
Kantrowitz, J. T., & Javitt, D. C. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.6 · Cited by 120
History of the Discovery of the Antipsychotic Dopamine D2 Receptor: A Basis for the Dopamine Hypothesis of Schizophrenia
Madras, B. K. (2013) · Journal of the History of the Neurosciences · doi:10.1080/0964704x.2012.678199 · Cited by 116
“The next step was to determine whether the antipsychotics could block neuronstimulated dopamine release, in contrast to spontaneous release (Seeman & Lee, 1975; Seeman, Staiman, & Chau-Wong, 1974).”
BackgroundResultInfluential
Classics in Chemical Neuroscience: Aripiprazole
Casey, A. B., & Canal, C. E. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00087 · Cited by 118
3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists
Rowley, M., Hallett, D. J., Goodacre, S. C., Moyes, C. R., Crawforth, J. M., Sparey, T. J., Patel, S. S., Marwood, R., Patel, S., Thomas, S., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004998 · Cited by 114
Increases in strychnine-insensiive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis
Ishimaru, M. J., Kurumaji, A., & Toru, M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91197-5 · Cited by 114
Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Egerton, A., Grace, A. A., Stone, J. M., Bossong, M. G., Sand, M. S., & McGuire, P. K. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.09.013 · Cited by 118
“Since the 1970s, abnormalities in dopaminergic neurotransmission formed the basis of the neurochemical hypothesis of psychosis (Creese et al., 1976; Seeman and Lee, 1975; Seeman et al., 1976).”
Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo
Gründer, G., Vernaleken, I., Müller, M. J., Davids, E., Heydari, N., Buchholz, H., Bartenstein, P., Munk, O. L., Stoeter, P., Wong, D. F., et al. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300103 · Cited by 114
“…the positive schizophrenic symptoms to an excess of dopaminergic neurotransmission, was formulated on the basis of observations that typical antipsychotic drugs block D2-like DA receptors in vitro (Carlsson, 1988) with affinities that correlate with clinical potency (Seeman and Lee, 1975).”
Background
Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine
Smith, R. C., & Davis, J. M. (1976) · Life Sciences · doi:10.1016/0024-3205(76)90170-3 · Cited by 111
Catecholamines released from cerebral cortex in the cat; decrease during sensory stimulation
Reader, T. A., de Champlain, J., & Jasper, H. H. (1976) · Brain Research · doi:10.1016/0006-8993(76)91051-9 · Cited by 110
Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs
Boyd, K. N., & Mailman, R. B. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_3 · Cited by 109
“…schizophrenia were a response to hyperactive dopaminergic signaling, a hypothesis that was supported by the ability of APDs to block D2 receptors and the psychotic effects induced by dopaminergic drugs (Carlsson and Lindqvist, 1963; Creese et al., 1976; Seeman et al., 1975; Seeman and Lee, 1975).”
Background
Effects of pimozide on lever pressing behavior maintained on an intermittent reinforcement schedule
Gray, T., & Wise, R. A. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90455-4 · Cited by 107
Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models
Lyon, L., Saksida, L. M., & Bussey, T. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2536-5 · Cited by 107
The History of the Psychopharmacology of Schizophrenia
Lehmann, H. E., & Ban, T. A. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200205 · Cited by 105
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Kumar, S., Chowdhury, S., & Kumar, S. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0394-8 · Cited by 103
Core, social and moral disgust are bounded: A review on behavioral and neural bases of repugnance in clinical disorders
Vicario, C. M., Rafal, R. D., Martino, D., & Avenanti, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.008 · Cited by 109
“…activity via brain stimulation results in a genuine subjective experience of disgust and disgust-related behaviors, as well as impaired recognition of disgust in others (Ostrowsky et al., 2000; Penfield and Faulk, 1955; Selimbeyoglu and Parvizi, 2010; Caruana et al., 2011; Papagno et al., 2016).”
Background
Antipsychotic Drug Action in Schizophrenic Patients: Effect on Cortical Dopamine Metabolism After Long-Term Treatment
Bacopoulos, N. C., SPOKES, E. G. S., Bird, E. D., & Roth, R. H. (1979) · Science · doi:10.1126/science.38504 · Cited by 102
Primary phospholipase C and brain disorders
Yang, Y. R., Kang, D., Lee, C., Seok, H., Follo, M. Y., Cocco, L., & Suh, P. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.11.003 · Cited by 104
Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate
Robison, A. J., Thakkar, K. N., & Diwadkar, V. A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.021 · Cited by 104
“The dopamine hypothesis garnered further clinical support because affinity for dopamine receptors was related to the effectiveness of antipsychotic drugs (126,127), later bolstered by postmortem studies (128,129), human molecular imaging [reviewed in (130)], and preclinical evidence (98,131) of increased striatal D2/3…”
Background
Effects of peripheral and central dopamine blockade on lateral hypothalamic self-stimulation: Evidence for both reward and motor deficits
Stellar, J. R. (1983) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(83)90466-5 · Cited by 101
Pharmacogenetics of Antipsychotics
Brandl, E. J., Kennedy, J. L., & Müller, D. J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900203 · Cited by 106
The role of prefrontal catecholamines in attention and working memory
Clark, K., & Noudoost, B. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00033 · Cited by 113
“Clinically effective antipsychotics appear to primarily target the D2 receptor (Seeman and Lee, 1975), and hyperstimulation of subcortical D2Rs is still considered a likely cause of the positive symptoms of the disorder; in contrast, a cortical, and specifically prefrontal, DA deficit may…”
Background
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1996) · Journal of Neuropsychiatry · doi:10.1176/jnp.8.2.223 · Cited by 100
Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801
Seillier, A., & Giuffrida, A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.02.007 · Cited by 99
The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors
Graff‐Guerrero, A., Mamo, D. C., Shammi, C., Mizrahi, R., Marcon, H., Barsoum, P., Rusjan, P., Houle, S., Wilson, A. A., & Kapur, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.43 · Cited by 100
Dopamine D-1 and D-2 receptors in relation to reward and performance: A case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs
Miller, R. J., Wickens, J. R., & Beninger, R. J. (1990) · Progress in Neurobiology · doi:10.1016/0301-0082(90)90005-2 · Cited by 98
Alterations of Serotonin Transmission in Schizophrenia
Abi‐Dargham, A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78005-9 · Cited by 98
DOPAMINE AND SCHIZOPHRENIA
Crow, T. J., Johnstone, E. C., Deakin, J. F. W., & Longden, A. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91807-9 · Cited by 98
Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses
Guilarte, T. R., Opler, M. G., & Pletnikov, M. V. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.11.008 · Cited by 97
“Subsequent studies showed that the therapeutic value of antipsychotic drugs was mediated by blocking D2-dopamine receptors (Seeman and Lee, 1975; Creese et al., 1976; Snyder, 1981).”
Background
Molecular substrates of schizophrenia: homeostatic signaling to connectivity
Landek‐Salgado, M. A., Faust, T. E., & Sawa, A. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.141 · Cited by 95
Relevance of Dopamine Autoreceptors for Psychiatry: Preclinical and Clinical Studies
Meltzer, H. Y. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.3.456 · Cited by 95
Dopamine receptors: Functions, subtypes and emerging concepts
Kaiser, C., & Jain, T. C. (1985) · Medicinal Research Reviews · doi:10.1002/med.2610050202 · Cited by 95
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
Dold, M., Samara, M. T., Li, C., Tardy, M., & Leucht, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009831.pub2 · Cited by 98
Neurochemical Individuality
Cravchik, A., & Goldman, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1105 · Cited by 94
Does the dopamine hypothesis explain schizophrenia?
Lau, C. I., Wang, H.-C., Hsu, J.-L., & Liu, M. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0011 · Cited by 102
Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Visanji, N. P., Gómez-Ramírez, J., Johnston, T. H., Pires, D., Voon, V., Brotchie, J. M., & Fox, S. H. (2006) · Movement Disorders · doi:10.1002/mds.21073 · Cited by 92
Dysregulation of the Norepinephrine Transporter Sustains Cortical Hypodopaminergia and Schizophrenia-Like Behaviors in Neuronal Rictor Null Mice
Siuta, M., Robertson, S. D., Kocalis, H. E., Saunders, C., Gresch, P. J., Khatri, V., Shiota, C., Kennedy, J. P., Lindsley, C. W., Daws, L. C., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000393 · Cited by 98
“For almost 50 years, schizophrenia research has centered on dopaminergic signaling as a crucial component of the etiology of the disease [23,24,25].”
Dopamine evoked inhibition of single cells of the feline putamen and basolateral amygdala.
Ben‐Ari, Y., & Kelly, J. S. (1976) · The Journal of Physiology · doi:10.1113/jphysiol.1976.sp011308 · Cited by 91
Autoreceptor-mediated changes in dopaminergic terminal excitability: Effects of striatal drug infusions
Tepper, J. M., Nakamura, S., Young, S. J., & Groves, P. M. (1984) · Brain Research · doi:10.1016/0006-8993(84)90598-5 · Cited by 91
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence
Hornykiewicz, O. (1978) · Neuroscience · doi:10.1016/0306-4522(78)90030-1 · Cited by 91
Improving Current Treatments for Schizophrenia
Marić, N. P., Jovicic, M. J., Mihaljevic, M. M., & Miljević, Č. (2016) · Drug Development Research · doi:10.1002/ddr.21337 · Cited by 89
“Later, the fact that dopamine receptor blockade was involved in the alleviation of psychosis symptoms by phenothiazine and butyrophenone was described in 60s and 70s, alongside with the notion that exacerbation of schizophrenia symptoms was following increased dopamine and/ or norepinephrine activity [Seeman and Lee,…”
Background
Structural Analysis of Phenothiazine Derivatives as Allosteric Inhibitors of the MALT1 Paracaspase
Schlauderer, F., Lammens, K., Nagel, D., Vincendeau, M., Eitelhuber, A. C., Verhelst, S. H. L., Kling, D., Chruściel, A., Ruland, J., Krappmann, D., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201304290 · Cited by 86
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia
Mu, Q., Johnson, K. A., Morgan, P. S., Grenesko, E. L., Molnar, C., Anderson, B. S., Nahas, Z. H., Kozel, F. A., Köse, S., Knable, M. B., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.033 · Cited by 87
Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
Cerveri, G., Gesi, C., & Mencacci, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s201726 · Cited by 84
“However, most of the agents developed in the past few decades still have a limited efficacy on NS, suggesting an urgent need for specific treatments for this neglected domain.(79,80) On one hand, NS have been found to improve in psychosocial and pharmacological interventions for psychosis that were not aimed primarily…”
Background
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy?
Turrone, P., Remington, G. J., & Nóbrega, J. N. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00008-8 · Cited by 83
Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature
Stone, J. M., Davis, J. M., Leucht, S., & Pilowsky, L. S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn009 · Cited by 87
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
George, M. S., Molnar, C., Grenesko, E. L., Anderson, B. S., Mu, Q., Johnson, K. A., Nahas, Z. H., Knable, M. B., FERNANDES, P. B., Juncos, J. L., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.011 · Cited by 85
Biochemical Actions of Neuroleptic Drugs: Focus on the Dopamine Receptor
Creese, I., Burt, D. R., & Snyder, S. H. (1978) · Springer eBooks · doi:10.1007/978-1-4613-4042-3_2 · Cited by 83
Glycine transport inhibitors in the treatment of schizophrenia
Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83
Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Roth, B. L., Sheffler, D. J., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00021-5 · Cited by 80
Possible relationship between glial cells, dopamine and the effects of antipsychotic drugs
Henn, F. A., ANDERSON, D. J., & Sellström, Å. (1977) · Nature · doi:10.1038/266637a0 · Cited by 81
Dopamine, fronto-striato-thalamic circuits and risk for psychosis.
Dandash, O., Pantelis, C., & Fornito, A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.08.020 · Cited by 89
Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
Purves-Tyson, T. D., Owens, S. J., Rothmond, D. A., Halliday, G. M., Double, K. L., Stevens, J., McCrossin, T., & Weickert, C. S. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.257 · Cited by 81
Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
Amato, D., Vernon, A. C., & Papaleo, F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 81
“For example, haloperidol and chlorpromazine show high binding affinity towards D2 receptors (Creese et al., 1976; Seeman and Lee, 1975) and are clinically effective when approximately 60–80% of central D2 receptors, are occupied by these drugs, which is now defined as the “antipsychotic therapeutic…”
Influential
Genetic markers of alcohol abuse
Ferguson, R. A., & Goldberg, D. M. (1997) · Clinica Chimica Acta · doi:10.1016/s0009-8981(96)06444-3 · Cited by 80
PRESYNAPTIC REGULATION OF RELEASE IN THE CENTRAL NERVOUS SYSTEM
Starke, K. (1979) · Elsevier eBooks · doi:10.1016/b978-0-08-021536-5.50012-5 · Cited by 79
D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex
Li, Y.-C., Kellendonk, C., Simpson, E. H., Kandel, E. R., & Gao, W.-J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109718108 · Cited by 78
“Transgenic mice were generated at Columbia University according to the methods described previously (1).”
BackgroundMethodResultInfluential
Molecular Pharmacology of High Voltage-Activated Calcium Channels
Doering, C. J., & Zamponi, G. W. (2003) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000008022.50702.1a · Cited by 78
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Fakhoury, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9697-5 · Cited by 81
Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
Hwu, H., Hong, C., Lee, Y.-L., Lee, P.-C., & Lee, S. F. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00134-6 · Cited by 78
“The neuroleptic response of schizophrenia has been thought to be due to the blocking effect of neuroleptics on the D2 receptor and related receptor families (Seeman and Lee 1975).”
Background
Relationship of the Actions of Neuroleptic Drugs to the Pathophysiology of Tardive Dyskinesia
Baldessarini, R. J., & Taray, D. (1979) · International review of neurobiology · doi:10.1016/s0074-7742(08)60636-4 · Cited by 78
MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia?
Vardigan, J. D., Huszar, S. L., McNaughton, C. H., Hutson, P. H., & Uslaner, J. M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.01.010 · Cited by 80
Release of Catecholamines, Serotonin, and Acetylcholine from Isolated Brain Tissue
Raiteri, M., Marchi, M., & Maura, G. (1984) · Springer eBooks · doi:10.1007/978-1-4684-4568-8_16 · Cited by 76
Deletion of PLCB1 gene in schizophrenia affected patients
Vasco, V. R. L., Cardinale, G., & Polonia, P. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01363.x · Cited by 78
“The complexity of the mechanisms underlying schizophrenia is witnessed by the involvement of a multitude of molecular pathways, including dopaminergic [4, 5], serotoninergic [6, 7], muscarinic [8–11] and glutamatergic signalling [12–14].”
Background
Mechanisms and Pharmacological Implications of Altering Calmodulin Activity
Weiss, B., & Wallace, T. L. (1980) · Elsevier eBooks · doi:10.1016/b978-0-12-171401-7.50021-5 · Cited by 76
The Significance of Dopamine for the Mode of Action of Neuroleptics and the Pathogenesis of Schizophrenia
van Praag, H. M. (1977) · The British Journal of Psychiatry · doi:10.1192/bjp.130.5.463 · Cited by 76
Dopamine D2 and D4 receptor ligands: relation to antipsychotic action
Wilson, J. M., Sanyal, S., & Tol, H. H. M. V. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00312-4 · Cited by 75
Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome.
Regeur, L., Pakkenberg, B., Fog, R., & Pakkenberg, H. (1986) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.7.791 · Cited by 75
Selective enhacement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia
Masana, M., Bortolozzi, A. A., & Artigas, F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000908 · Cited by 78
“A general enhancement of brain dopaminergic neurotransmission in schizophrenia was suggested by pharmacological evidence (Creese et al. 1976 ; Seeman & Lee, 1975).”
Classics in Chemical Neuroscience: Haloperidol
Tyler, M. W., Zaldívar-Díez, J., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00018 · Cited by 77
Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: Probable effects of family history of schizophrenia?
Nimgaonkar, V. L., Zhang, X. R., Caldwell, J. G., Ganguli, R., & Chakravarti, A. (1993) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320480408 · Cited by 74
Dopamine, prediction error and associative learning: A model-based account
Smith, A. J., Li, M., Becker, S., & Kapur, S. (2006) · Network Computation in Neural Systems · doi:10.1080/09548980500361624 · Cited by 74
“…of dopamine enhancing drugs such as amphetamine can induce psychosis in otherwise healthy people (Bell 1973; Connell 1958), and the correlation between a drug’s antipsychotic efficacy and the ability of that drug to block the dopamine D2-receptor is striking (Seeman & Lee 1975; Kapur & Mamo 2003).”
Background
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Davis, R. E., & Correll, C. U. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1174577 · Cited by 72
“This hypothesis was historically based on the observation that all clinically effective antipsychotic drugs have potent antagonist activity at dopamine D2 receptors, and that the therapeutic efficacy of these compounds is highly correlated with occupancy of striatal D2 receptors [29,30].”
Background
Inhibition of [3H]dopamine accumulation in rat striatal synaptosomes by psychotropic drugs
Hyttel, J. (1978) · Biochemical Pharmacology · doi:10.1016/0006-2952(78)90159-4 · Cited by 72

Authors: Seeman, P., & Lee, T.
Affiliations: University of Toronto (CA)
ORCID: Seeman, P.
Lee, T.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 1975-06-20
Volume: 188
Issue: 4194
Pages: 1217-1219
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.1145194
OpenAlex: W2006122360
Cited by: 869
References: 35
Citations by year: 2026: 5 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 22 · 2021: 13 · 2020: 18 · 2019: 36 · 2018: 21 · 2017: 30 · 2016: 26 · 2015: 28 · 2014: 37 · 2013: 23 · 2012: 32
FWCI: 62.55
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: antipsychotic drugs, presynaptic dopamine release, striatum, spiperone, thioridazine, butyrophenones, phenothiazines, reserpine, pimozide, clozapine, butaclamol, stereoisomers, acetylcholine release, GABA release, schizophrenia
MeSH terms: Acetylcholine, Animals, Corpus Striatum, Dopamine, Dose-Response Relationship, Drug, Electric Stimulation, gamma-Aminobutyric Acid, Haloperidol, Humans, Male, Neurons, Neurosecretion, Schizophrenia, Tranquilizing Agents, Tritium, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks